US 10857205
Use of a VEGF antagonist to treat angiogenic eye disorders
granted A61KA61K2039/505A61K38/179
Quick answer
US patent 10857205 (Use of a VEGF antagonist to treat angiogenic eye disorders) held by REGENERON PHARMACEUTICALS, INC. expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 3
- CPC classes
- A61K, A61K2039/505, A61K38/179, A61K9/0048, A61P